NASDAQ:DRUG

Bright Minds Biosciences (DRUG) Stock Price, News & Analysis

Bright Minds Biosciences logo
$22.61 -0.50 (-2.16%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$22.35 -0.26 (-1.16%)
As of 11/16/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Bright Minds Biosciences Stock (NASDAQ:DRUG)

Advanced

Key Stats

Today's Range
$21.56
▼
$24.28
50-Day Range
$18.93
▼
$66.91
52-Week Range
$17.40
▼
$123.75
Volume
220,514 shs
Average Volume
281,147 shs
Market Capitalization
$220.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$126.29
Consensus Rating
Moderate Buy

Company Overview

Bright Minds Biosciences is a clinical-stage biotechnology company developing medicines for neurological and psychiatric disorders. Its research focuses on compounds that act on serotonin receptors, which play a role in regulating brain activity.

The company’s development programs include BMB-101, a serotonin 5-HT2C receptor agonist being investigated for seizure disorders. Bright Minds is developing its candidates as potential treatments; it does not market approved products.

AI Generated. May Contain Errors.

Bright Minds Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

DRUG MarketRank™: 
2.75295838319 of 5 stars

Bright Minds Biosciences scored higher than 55% of companies evaluated by MarketBeat, and ranked 380th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bright Minds Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 9 buy ratings, 2 hold ratings, and no sell ratings.

  • Upside Potential

    Bright Minds Biosciences has a consensus price target of $126.29, representing about 458.5% upside from its current price of $22.61.

  • Amount of Analyst Coverage

    Bright Minds Biosciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Bright Minds Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Bright Minds Biosciences are expected to decrease in the coming year, from ($2.93) to ($6.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bright Minds Biosciences is -10.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bright Minds Biosciences is -10.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bright Minds Biosciences has a P/B Ratio of 2.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Bright Minds Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    14.36% of the float of Bright Minds Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Bright Minds Biosciences has a short interest ratio ("days to cover") of 7.91.
  • Change versus previous month

    Short interest in Bright Minds Biosciences has recently decreased by 3.43%, indicating that investor sentiment is improving.
  • Dividend Yield

    Bright Minds Biosciences does not currently pay a dividend.

  • Dividend Growth

    Bright Minds Biosciences does not have a long track record of dividend growth.

  • News Sentiment

    Bright Minds Biosciences has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Bright Minds Biosciences this week, compared to 3 articles on an average week.
  • Search Interest

    2 people have searched for DRUG on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bright Minds Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    42.66% of the stock of Bright Minds Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    40.52% of the stock of Bright Minds Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bright Minds Biosciences' insider trading history.
Receive DRUG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bright Minds Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DRUG Stock News Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Headlines

DRUG Stock Analysis - Frequently Asked Questions

Bright Minds Biosciences' stock was trading at $78.04 at the start of the year. Since then, DRUG stock has decreased by 71.0% and is now trading at $22.61.

Bright Minds Biosciences Inc. (NASDAQ:DRUG) issued its earnings results on Friday, August, 14th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($1.22) by $1.05.

Shares of Bright Minds Biosciences reverse split on the morning of Friday, July 14th 2023.The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Bright Minds Biosciences' top institutional shareholders include State Street Corp (1.26%).
View institutional ownership trends
.

Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bright Minds Biosciences investors own include NVIDIA (NVDA), Rigetti Computing (RGTI), Archer Aviation (ACHR), IonQ (IONQ), SoundHound AI (SOUN), Tesla (TSLA) and Palantir Technologies (PLTR).

Company Calendar

Last Earnings
8/14/2026
Today
11/16/2026
Next Earnings (Estimated)
12/22/2026
Fiscal Year End
9/30/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:DRUG
CIK
1827401
Fax
N/A
Employees
25
Year Founded
2019

Price Target and Rating

High Price Target
$220.00
Low Price Target
$37.00
Potential Upside/Downside
+458.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.08)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.74 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-12.46%
Return on Assets
-12.30%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
122.00
Quick Ratio
122.00

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.33 per share
Price / Book
2.71

Miscellaneous

Outstanding Shares
9,730,000
Free Float
5,580,000
Market Cap
$220.00 million
Optionable
Optionable
Beta
-5.11

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (NASDAQ:DRUG) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners